There is now good evidence that non-coding sequence variants are involved in the heritability of many common complex traits. The current 'gold standard' approach for assessing functionality is the in vitro reporter gene assay to assess allelic differences in transcriptional activity, usually followed by electrophoretic mobility shift assays to assess allelic differences in transcription factor binding. Although widely used, these assays have inherent limitations, including the lack of endogenous chromatin context. Here we present a more contemporary approach to assessing functionality of non-coding sequence variation within the Vanin-1 (VNN1) promoter. By combining 'gold standard' assays with in vivo assessments of chromatin accessibility, we greatly increase our confidence in the statistically assigned functional relevance. The standard assays revealed the À137 single nucleotide variant to be functional but the À587 variant to have no functional relevance. However, our in vivo tests show an allelic difference in chromatin accessibility surrounding the À587 variant supporting strong functional potential at both sites. Our approach advances the identification of functional variants by providing strong in vivo biological evidence for function.
INTRODUCTION
There is growing evidence that non-coding genetic variation has an important role in the determination of individual susceptibility to complex disease. 1, 2 Single nucleotide variants (SNVs) account for approximately 90% of all known sequence variation, most of which is located in non-coding regions of the genome. 3 It is therefore likely that a significant number of SNVs that influence phenotype, that is, functional variants, actually lie outside amino-acid coding regions of genes and affect the regulation of gene expression as opposed to protein sequence and function. 4, 5 Current estimates from the 1000 genomes data indicate that there are as many non-coding functional variants as coding ones. 3 One of the greatest challenges currently facing genetics is determining which non-coding genetic variants have a functional effect on gene expression rather than being neutral.
The primary purpose of the study is to identify the functional variants that have been identified previously using an integrative genetics approach. We have previously used this approach to identify novel cis-acting genes that correlate with HDL cholesterol levels, a predictive determinant for cardiovascular disease. 6 Leukocyte-based RNA samples from 1240 individuals in the San Antonio Family Heart Study (SAFHS) 7 were used to obtain genome-wide transcriptional profiles. Analysis identified 67 cis-regulated transcripts whose expression levels significantly correlated with HDL-C levels. One gene, Vanin-1 (VNN1 (MIM No. 603570)), showed strong support for both cis-regulation and positive correlation with HDL-C levels.
VNN1 is a pantetheine hydrolase (pantetheinase) 8 that catalyses the hydrolysis of pantetheine to pantothenic acid (Vitamin B5) and cysteamine, a potent antioxidant. 9, 10 Administration of pantethine, the dimer of pantetheine, to hyperlipidemic subjects results in the lowering of serum TG, low-density lipoproteins and ApoB, whilst increasing HDL-C and ApoA levels, 11, 12 supporting our data implicating Vanin-1 in lipid biosynthesis (for a review, see Kaskow et al 13 ) .
The objective of the current study was the identification and molecular characterization of the functional cis-acting sequence variation in the promoter of VNN1. The 'gold standard' approach for determining whether cis-regulatory elements such as SNVs regulate gene expression consists of the reporter gene assay [14] [15] [16] and the electrophoretic mobility shift assay (EMSA). 17, 18 In the reporter gene assay, allelic promoter regions are cloned upstream of a reporter gene such as luciferase, transfected into relevant cell lines and assayed for reporter gene activity as a measure of transcriptional activity. Differences in activity between the allelic constructs are considered to reflect functional differences. The EMSA is used to detect allelic differences in transcription factor binding when comparing nucleotide sequence probes carrying specific SNVs (for a review of these approaches, see Knight 19 ) Although these in vitro approaches have traditionally been considered adequate to ascertain the functionality of sequence variation, there are many variables that can confound the results and render the ascertainment of function inconclusive, as we have shown previously. 20 This led us to develop strategies that assess function in an in vivo context. 21 Here we use traditional approaches and also further develop in vivo approaches 22 to validate statistically prioritized variants within the VNN1 promoter. In addition, we illustrate the potential of a novel, robust method for assessing variant's functionality on a genome-wide level 23 that we have developed based on next-generation sequencing technology. The combination of the 'gold standard' approaches and our more rigorous in vivo tests allows for a more confident assessment of whether a variant does indeed regulate gene expression and yields insights into the allele-specific mechanism of action.
METHODS

Nucleotide numbering
Numbering of nucleotides reflects transcription initiation site numbering as defined before. 6 The transcription initiation site is defined as the nucleotide 13 basepairs upstream of the A of the ATG translational initiation codon of VNN1 (GenBank accession number NG_012147.1). In reference to the hg19 genome, the translation initiation codon is located at position chr6: 133035174 with À137 (rs4897612:G4T; À150) at chr6:133035325 and À587 (rs2050153:G4A; À600) at chr6:133035775 according to 1-based numbering. The alternative translation initiation numbering is provided in brackets at the first mention in the text. All SNVs can be found in the dbSNP database. 24 
Statistical genetics
The description of the genotyping and statistical genetic methods used to prioritize the VNN1 promoter variants have been previously described by Goring et al. 6 The population stratification, measured genotype, quantitative trait disequilibrium test (QTDT) and quantitative trait linkage disequilibrium (QTLD) results for the À137 SNP (rs4897612:G4T) were computed on the inverse-normalized VNN1 mRNA phenotype using the qtld command in the SOLAR computer package. 25 This procedure performs a test for population stratification as well as the commonly used association tests, QTDT 26 and the measured genotype test. 27 The QTDT procedure is not limited to the scoring of allele transmission from parents to offspring but assesses the entire pedigree structure of the SAFHS cohort, thus increasing the power to detect an association. 28 The measured genotype test uses a standard threshold model assuming an underlying normal distribution of liability. The measured genotype graph for the À137 SNP was generated using geom_boxplot in ggplot2. 29 
Cell culture
The Jurkat E6-1 cell line (ATCC No. TIB-152) was cultured in RPMI-1640 with L-glutamine (Life Technologies Co., Grand Island, NY, USA) supplemented with 100 g/ml of penicillin/streptomycin (Life Technologies Co.) and 10% heat inactivated FBS (Life Technologies Co.). Cells were maintained at 37 1C with 5% CO 2 according to cell-specific guidelines. Epstein Bar Virus -transformed lymphoblastoid cell lines were created from the SAFHS cohort. Cell lines A04210, A01223, A01518, A02238, A00263, A01721 and A01897 were maintained as described above.
Reporter gene assays
To create reporter gene constructs, approximately 2 kilobasepairs (kb) of the VNN1 proximal promoter from À2021 to þ 14 was cloned into the pGL4.10 vector between the Acc65I and HindIII restriction cut sites immediately upstream of the firefly luciferase reporter gene. A construct representing the À587G/ À137G haplotype was initially generated and subsequently each variant was mutated to the other allele using the Quikchange II Site-Directed mutagenesis kit (Agilent Technologies Pty Ltd, Melbourne, VIC, Australia) according to the manufacturer's instructions. Genotypes were confirmed by sequencing.
Mycoplasma-free Jurkat E6-1 cells were transiently transfected using the Amaxa Nucleofector II system (Lonza Inc., Walkersville, MD, USA) according to the manufacturer's instructions. In brief, 2 Â 10 6 cells were harvested on day 7 of growth and resuspended in solution V. One microgram of DNA and 100 ng pRL-TK control vector was transfected per reaction using the setting X-001. Twenty-four hours post transfection, the cells were harvested, and luciferase activity was measured using the Dual luciferase Reporter Assay System (Promega Co., Sydney, NSW, Australia). Statistical significance was determined by the Student's unpaired t-test. Po0.05 was considered significant.
EMSA
Complementary 5
0 biotinylated oligonucleotides representing both allelic forms of the promoter variants were obtained commercially (Operon Biotechnologies, Inc., Huntsville, AL, USA). The sequences of the EMSA oligonucleotides VNN137T, VNN137G, VNN587G and VNN587A: 5 0 are shown in Table 1 . Nuclear extract preparation, binding reactions and gel analysis and detection were as described previously. 6, 30 For EMSA supershift reactions, 500 ng human Sp1 supershift-grade antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was incubated with the nuclear extract for 30 min on ice, then incubated with the labeled oligonucleotide for 30 min on ice before analysis.
Chromatin arrangement assay
Chromatin arrangement assays were performed as previously described 22, 31, 32 with the following modifications. Nuclei were prepared and digested with nuclease using approximately 1 Â 10 7 genotyped cells from the SAFHS cohort. DNA were purified using the QIAamp DNA blood mini kit (Qiagen Pty Ltd, Doncaster, VIC, Australia). Quantitative real-time PCR was performed using 100 ng DNA, 0.5 mM of primers ( À137 Chart F and À137 Chart R or À587 Chart F and À587 Chart R-see Table 1 ) and SensiMix SYBR No Rox (Bioline (Aust) Pty Ltd, Alexandria, NSW, Australia) in a final reaction volume of 20 ml. Thermal cycling conditions for the CFX96 Real-Time Detection System (Bio-Rad Laboratories Inc., Hercules, CA, USA) were as follows: 95 1C for 10 min; followed by 40 cycles of 95 1C for 15 s, 58 1C for 15 s and 72 1C for 15 s. Percentage of chromatin accessibility was calculated as a ratio of relative abundance of digested to undigested amplicon, a measurement calculated using the CFX Manager software (Bio-Rad Laboratories). Statistics were performed using GraphPad Prism v4 (GraphPad Software, San Diego, CA, USA). Statistical significance was determined by the Student's unpaired t-test. Po0.05 was considered significant.
Bisulfite sequencing
Genomic DNA was isolated from cultured human leukocyte cell lines and purified using DNA Blood mini columns (Qiagen). Purified DNA was treated with bisulfite to convert unmethylated cytosine bases into uracils and subsequently purified using EpiTect spin columns (Qiagen). The converted DNA was enriched for the VNN1 gene promoter by PCR using primers VNNB F Table 1 Sequences of EMSA and PCR oligonucleotides used in this study
and VNNB R ( Chromatin arrangement-sequencing (CHA-seq)
Nuclei were isolated from 1 Â 10 7 cells of an immortalized leukocyte cell line (ID: A01721) heterozygous at À137 and À587 of VNN1 identified by our previous sequence analysis of the VNN1 promoter. 6 Isolated nuclei were digested with micrococcal nuclease (New England Biolabs Inc., Ipswich, MA, USA) for 20 min at 37 1C, and DNA purified using DNA Blood mini columns (Qiagen). DNA fragment sizes, including mononucleosomal and dinucleosomal fragments as well as intervening sizes (140-280 basepairs), were isolated following agarose gel electrophoresis to maximize the capture of non-nucleosomal nuclease sensitivity. Purified fragments were prepared for next-generation sequencing using the NEBNext DNA sample prep kit (New England Biolabs) according to the manufacturer's protocol. The prepared library was enriched for VNN1 sequences using the SureSelect DNA capture array (Agilent Technologies Inc., Santa Clara CA, USA), then sequenced on an Illumina Genome Analyser II (Illumina Inc., San Diego, CA, USA). The sequence data were analyzed using the Integrative Genomics Viewer (IGV) 2.0 software. 34 
RESULTS
Identification of putative functional variants within the VNN1 promoter
To identify cis-acting functional elements within the VNN1 promoter, we previously re-sequenced 2 kb of proximal promoter upstream from the VNN1 transcriptional start site and identified 22 promoter variants in the SAFHS founder population. 6 The 6 best candidate variants were typed in all 1240 SAFHS samples to assess association with VNN1 transcript level in the larger population. Analysis revealed five variants strongly associated with VNN1 transcript abundance; the À137 (rs4897612:G4T) and À587 (rs2050153:G4A) variants showing the strongest relationship. In the current study, the population stratification, measured genotype, QTDT and QTLD results for the À137 variant were computed on the inversenormalized VNN1 mRNA phenotype. The measured genotype results for the À137 variant, demonstrating an additive genetic effect, are shown in Figure 1 . The strong linkage disequilibrium (LD) between the À137 and À587 SNPs (r 2 ¼ 0.99) impeded further statistical prioritization, as the two variants were providing essentially identical genetic information. Functional validation was necessary to resolve whether one or both of the variants was responsible for influencing the expression of the mRNA.
'Gold standard' functional tests of the À137 and À587 VNN1 promoter SNPs In a previous study, we reported the identification of several SNVs within the proximal promoter of the VNN1 gene that showed significant association. The variant most highly correlated with VNN1 transcript levels in leukocytes ( À137) was also shown by EMSA to exhibit differential nuclear factor binding supporting a potential regulatory role. 6 To more fully assess the functional attributes of the À137 SNP and the next most significantly correlated variant at position À587, we have now used the 'gold standard' approaches for characterizing variant functionality. Data from the interrogation of the ENCODE databases using RegulomeDB 35 did not provide any convincing evidence that the SNPs were located in a transcriptionally active region, although there is a paucity of ENCODE data for lymphocytes, the cell type with which the original study was done. Also, no ChIP-seq data were available for transcription factor Sp1, which we have tentatively identified as being relevant previously, 6 and no evidence was found for the binding of miRNA or other non-coding RNAs. For the gold standard tests, a 2-kb region of the VNN1 promoter was inserted upstream of a firefly luciferase reporter gene. A construct representing the major À137T haplotype ( À137T/ À587G) was generated initially and subsequently mutated to the other allele to allow the independent assessment of variants at each site. Reporter gene analysis indicated that the À137G allele showed significantly higher expression (1.36-fold, P ¼ 0.005) than the T allele (Figure 2a) . The functional attributes of the À137 alleles were also tested in the context of both À587 alleles. The results indicated that the À587 SNP alleles did not influence transcriptional activity differences due to the À137 alleles in this assay.
To determine whether the allelic difference in transcriptional activity related to differences in transcription factor binding, EMSA was performed. The results confirmed our previous results that showed allele-specific difference in transcription factor binding at the À137 SNP. As previous bioinformatic analysis indicated the presence of a putative Sp1 transcription factor binding site in the À137G region, 6 supershift EMSA was done using an anti-Sp1 antibody. The major complex interacting with the À137G sequence was supershifted with this antibody, indicating that the major À137G complex contained the activating transcription factor Sp1 (Figure 2b ). This is consistent with the reporter gene analysis where the À137G allelic reporter showed an increase in transcriptional activity compared with the À137T allele. In contrast, no binding was seen for either the À587 G or A allele (Figure 2c ). Taken together, these 'gold standard' tests would indicate that the À137 SNP is functional, whereas the À587 variant is not. Figure 1 Box and whisker plot for the measured genotype analysis of the À137 SNP on VNN1 mRNA abundance in leukocytes from the SAFHS participants. The absence of the G allele strongly impairs expression (P ¼ 5.7 Â 10 À83 ). The mRNA phenotype has been inverse-normalized for this analysis, resulting in a population mean of zero, with units approximating the SDs.
Functional variants in the
Allele-specific chromatin accessibility analysis of the À137 and À587 SNPs One limitation of the 'gold standard' approaches is that they fail to assess variant function in their in vivo chromosomal context. As chromatin context is dependent on DNA sequence per se as well as methylation status, variants can potentially alter the conformation of the surrounding chromatin and result in distinct transcriptional potential and hence alter the regulation of a gene. Given that the À587 G variant allele occurs as part of a CpG dinucleotide and is a potential site for methylation, the development of a chromatin accessibility assay was particularly important in assigning function. To determine the endogenous chromatin conformation around both the À137 and À587 SNPs, genotyped lymphoblastoid cell lines from the SAFHS population were used to perform chromatin arrangement by real-time PCR (CHART-PCR) assays. 22, 32 The results showed that À587 A/A homozygotes displayed a greater chromatin accessibility (27%) around the À587 site than À587 G/G homozygotes (10%, Figure 3 ). As expected, the À587 heterozygotes showed an intermediate level of accessibility (16%). Similar results were obtained for the À137 SNP, where the T allele (27%) showed a greater accessibility than the G allele (13%) with intermediate levels for the heterozyote À137 G/T lines (19%). Overall, the results indicate that both the À587 and the À137 SNPs differentially influence chromatin arrangement and potentially the expression of VNN1.
Allele-specific methylation status of the À587 SNP region Bioinformatic analysis 36 of the VNN1 promoter region surrounding the À587 and À137 SNPs indicated the presence of a CpG island encompassing the À587 site, the predicted extent of which was different for each allele. For the À587 G allele (which is in LD with the À137 T allele), the region was 264 bp in length, and for the A allele, a predicted 204 bp region (Figure 4a ). Although no data were available for lymphocytes, ENCODE data also supported the presence of a CpG island encompassing the À587 variant in brain tissue. 35 As the chromatin accessibility assay results indicated that the À587 G variant was in a region of condensed chromatin, it was of interest to determine whether the À587 G nucleotide methylation status was directly responsible for the difference predicted. We therefore performed bisulfite sequence analysis on genotyped lymphoblastoid cell lines from the SAHFS population to assess the DNA methylation status of the VNN1 promoter CpG island in the region in which the À587 SNP was embedded (Figure 4b ). The À587 G site in both homozygotes and heterozygotes shows near complete cytosine Functional variants in the Vanin-1 Gene BJ Kaskow et al methylation (on the opposite strand). In fact, all CpG dinucleotides displayed heavy methylation, except at the À720 ( À733) CpG site. For this site, the methylation pattern correlated with À587 genotype. On haplotypes carrying the À587 G allele, the À720
CpG site was generally unmethylated. Conversely, when the À587 A allele is present, the À720 CpG site was almost exclusively cytosine methylated. This pattern was present even in the heterozygous lines, indicating that the allele-specific pattern is not cell line specific but is rather determined by genotype. The functional consequence of this is yet to be determined but is likely responsible for the À587 allelic differences apparent in chromatin arrangement.
Assessment of chromatin arrangement at the À587 SNP using a novel genome-wide assay As our results suggested that the effects of allelic variation may be manifest at regions remote from the actual site of sequence difference, we have translated the CHART-PCR assay into a genome-wide format (CHA-seq) in order to assess allele-specific differences in chromatin arrangement across an extended genomic region. A micrococcal nuclease-digested genomic library was prepared from a À587 G/A heterozygous cell line from the SAFHS cohort. The library was subjected to next-generation sequencing to map the nuclease digestion sites. The results showed that the region surrounding the À587 SNP displayed a periodicity in the number of nuclease cut sites consistent with the positioning of the nucleosomes in the region (Figure 5a ). Comparison of the number of sequenced library fragments ending at a particular nucleotide (and hence mapping the sites of digestion by the nuclease) for each À587 variant indicated an allele-specific bias in the digestion pattern (Figures 5a and b) . Only 12% of the total number of fragments carried À587 G, with the majority carrying the A allele (88%). This is consistent with the region of the haplome carrying the À587G allele being subject to greater chromatin condensation than that carrying the A allele.
DISCUSSION
The 'gold standard' functional tests have been useful over the past two decades as a test for determining the functionality of genetic variants. However, both the reporter gene and EMSA assays are unreliable in a number of respects. We have developed strategies that initially involves a statistical prioritization of sequence variants based on comprehensive genotyping and correlation with transcript expression levels, 6 and in the current study, application of the 'gold standard' functional tests followed by novel in vivo tests that quantitate differences in chromatin arrangement as a measure of functional difference. Our strategy serves to greatly increase confidence in assigning function to a particular variant. Our results indicated that the two SNPs within the VNN1 promoter, previously predicted to be functional following extensive statistical interrogation of transcript levels from the SAFHS, 6 were functional. The 'gold standard' assays established that the À137 SNP was functional and showed a higher level of transcriptional activity for the À137G allele that is consistent with the ability of this allele to preferentially bind the activating transcription factor Sp1 in EMSA. In contrast, the À587 SNP alleles displayed no differences in either transcriptional activity or transcription factor binding.
However, application of our in vivo tests show a significant allelic difference in chromatin accessibility surrounding the À587 SNP and consequently indicates strong functional potential at this variant also. As one of the alleles at À587 is contained within a CG dinucleotide and hence is a potential site of cytosine methylation, bioinformatic analysis of the region surrounding the À587 SNP revealed allele-specific differences in the extent of the CpG island predicted to be present in the VNN1 promoter. Assessment of the methylation status of the region surrounding the À587 SNP revealed an allele-specific methylation pattern at a single CG dinucleotide approximately 120 bp upstream of the À587 SNP, establishing that allele-specific chromatin differences can be seen at sites remote from the actual genetic variation. Similar results have been observed previously, 37 where two PBL and one CD34-positive cell samples showed a similar pattern to our lymphoblastoid cell lines, of differential CpG methylation at the À720 site. However, in contrast to our results, the results from the previous study suggest that the genotype at À587 does not correlate with À720 methylation status. Given the almost complete LD between À587 and À137 in our SAFHS population, it is possible that the effects seen at the À720 site are due to allele-specific events at the À137 site. In partial support of this, the reporter gene analysis shows that the allele-specific effects seen for the À137 SNP are independent of À587 genotype.
A model to provide a possible explanation for the allele-specific methylation events is that À137G allele-specific Sp1 transcription factor binding leads to allele-specific chromatinization of a restricted promoter region upstream of the VNN1 gene and consequent increased gene expression ( Figure 6 ). We propose that regulatory factor/s are able bind to a region upstream of the À720 site in the À137G allele due to this restricted chromatinization (Figure 6b) , whereas in the À137T allele the extended CpG island blocks binding (Figure 6a ). The upstream factor may serve to increase transcription via interaction with the downstream Sp1 binding at À137 (Figure 6b ) or otherwise by remodeling the chromatin at the CpG island leading to derepressed Sp1-mediated activation. It is likely that the genotype at the À137 site dictates both the occupancy of the Sp1 site and also the chromatin conformation of the VNN1 upstream promoter region and serves to regulate genotype-specific VNN1 expression.
In any case, the results obtained from this study provide a platform to investigate the allele-specific regulation of the VNN1 gene and the influence of the genetic variation on CVD-related phenotypes. We will use the functional cis-regulatory SNP/s identified here to define, by association analyses in our lymphocyte transcriptome data set, those genes that are obligately downstream of VNN1. Identification of À137 as a true functional SNP also allows a simplified re-evaluation of genetic associations with multiple CVD risk-related phenotypes (including triglycerides, HDL-C, carotid wall thickness). As we have shown previously, 38 the functional effects of SNP variation are often only manifest under specific tissue-specific or stimulus-specific conditions. Although our current studies were carried out in genotyped lymphocytes or lymphocyte cell lines, a cell type that is easily obtained, many functional studies will be limited due to the context in which a functional effect will be seen. One of the potential limitations of our in vivo assays, which require the isolation of nuclei from genotyped cells, is the availability of the appropriate cell or tissue type, but results from our own expression QTL studies 6 and those of others 39 indicate that significant functional information can be obtained for genes that are not normally expressed in the cell type used.
Our approach to the identification of non-coding functional variation, involving statistical prioritization of variants that are associated with transcript levels of the locus, followed by the application of a comprehensive suite of standard as well as new in vivo tests for function, will greatly improve the positive identification of non-coding functional variants by reducing the levels of false-positive ascertainment in addition to providing more compelling evidence with respect to the mechanism of action. Figure 6 Model of the interplay between variants at the À137 and À587 sites and the upstream CpG island of the VNN1 promoter. (a) The À137T/ À587G haplotype induces methylation of a region that extends past the À720 site blocking binding of regulatory factors to sites upstream. (b) In the À137G/ À587A haplotype, the À720 site is methylated but the À587 site is not, leading to a restricted CpG island methylation which allows binding of regulatory factors upstream of À720. Also, the activating transcription factor Sp1 is able to bind at the À137G site. This has the effect of enhancing transcription by direct or indirect interaction between the upstream regulatory factor and the Sp1 transcription factor.
